PortfoliosLab logo
ITCI vs. ADSK
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between ITCI and ADSK is 0.32, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Performance

ITCI vs. ADSK - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Intra-Cellular Therapies, Inc. (ITCI) and Autodesk, Inc. (ADSK). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Fundamentals

Market Cap

ITCI:

$14.05B

ADSK:

$63.77B

EPS

ITCI:

-$0.73

ADSK:

$5.13

PEG Ratio

ITCI:

0.00

ADSK:

1.76

PS Ratio

ITCI:

20.63

ADSK:

10.40

PB Ratio

ITCI:

12.23

ADSK:

24.33

Total Revenue (TTM)

ITCI:

$535.77M

ADSK:

$4.71B

Gross Profit (TTM)

ITCI:

$488.71M

ADSK:

$4.27B

EBITDA (TTM)

ITCI:

-$95.53M

ADSK:

$1.21B

Returns By Period


ITCI

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

3Y*

N/A

5Y*

N/A

10Y*

N/A

ADSK

YTD

0.11%

1M

14.04%

6M

-2.04%

1Y

33.76%

3Y*

15.63%

5Y*

8.52%

10Y*

18.03%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Intra-Cellular Therapies, Inc.

Autodesk, Inc.

Risk-Adjusted Performance

ITCI vs. ADSK — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ITCI
The Risk-Adjusted Performance Rank of ITCI is 9797
Overall Rank
The Sharpe Ratio Rank of ITCI is 9494
Sharpe Ratio Rank
The Sortino Ratio Rank of ITCI is 9898
Sortino Ratio Rank
The Omega Ratio Rank of ITCI is 9797
Omega Ratio Rank
The Calmar Ratio Rank of ITCI is 9999
Calmar Ratio Rank
The Martin Ratio Rank of ITCI is 9696
Martin Ratio Rank

ADSK
The Risk-Adjusted Performance Rank of ADSK is 8282
Overall Rank
The Sharpe Ratio Rank of ADSK is 8787
Sharpe Ratio Rank
The Sortino Ratio Rank of ADSK is 8181
Sortino Ratio Rank
The Omega Ratio Rank of ADSK is 8080
Omega Ratio Rank
The Calmar Ratio Rank of ADSK is 8080
Calmar Ratio Rank
The Martin Ratio Rank of ADSK is 8282
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

ITCI vs. ADSK - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Intra-Cellular Therapies, Inc. (ITCI) and Autodesk, Inc. (ADSK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.



Loading data...

Dividends

ITCI vs. ADSK - Dividend Comparison

Neither ITCI nor ADSK has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

ITCI vs. ADSK - Drawdown Comparison


Loading data...

Volatility

ITCI vs. ADSK - Volatility Comparison


Loading data...

Financials

ITCI vs. ADSK - Financials Comparison

This section allows you to compare key financial metrics between Intra-Cellular Therapies, Inc. and Autodesk, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00500.00M1.00B1.50BAprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025
199.22M
1.64B
(ITCI) Total Revenue
(ADSK) Total Revenue
Values in USD except per share items

ITCI vs. ADSK - Profitability Comparison

The chart below illustrates the profitability comparison between Intra-Cellular Therapies, Inc. and Autodesk, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

89.0%90.0%91.0%92.0%93.0%AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025
89.8%
90.6%
(ITCI) Gross Margin
(ADSK) Gross Margin
ITCI - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Intra-Cellular Therapies, Inc. reported a gross profit of 178.82M and revenue of 199.22M. Therefore, the gross margin over that period was 89.8%.

ADSK - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Autodesk, Inc. reported a gross profit of 1.49B and revenue of 1.64B. Therefore, the gross margin over that period was 90.6%.

ITCI - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Intra-Cellular Therapies, Inc. reported an operating income of -29.20M and revenue of 199.22M, resulting in an operating margin of -14.7%.

ADSK - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Autodesk, Inc. reported an operating income of 366.00M and revenue of 1.64B, resulting in an operating margin of 22.3%.

ITCI - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Intra-Cellular Therapies, Inc. reported a net income of -16.89M and revenue of 199.22M, resulting in a net margin of -8.5%.

ADSK - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Autodesk, Inc. reported a net income of 303.00M and revenue of 1.64B, resulting in a net margin of 18.5%.